What changed: Metastatic castration-resistant prostate cancer
Every dated change on the records linked to Metastatic castration-resistant prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval13Regulatory6Trial result10Milestone10This record1
September 2026 · 1
March 2025 · 1
2025 · 3
- 2025ApprovalLutetium-177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan approved in US
PSMA+ mCRPC after ARPI, before chemotherapy
- 2025Trial resultECLIPSEECLIPSE reported
rPFS significantly improved.
- 2025MilestoneECLIPSEECLIPSE: 177Lu-PSMA-I&T meets its endpoint
A milestone in how this cancer is treated.
2024 · 1
August 2023 · 1
June 2023 · 1
May 2023 · 1
2023 · 4
March 2022 · 1
2022 · 5
- 2022ApprovalLutetium-177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan approved in EU
mCRPC post-ARPI and taxane; pre-chemo 2025
- 2022ApprovalLutetium-177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan approved in US
PSMA+ mCRPC after ARPI and taxane
- 2022Trial resultMAGNITUDEMAGNITUDE reported
BRCA cohort rPFS HR 0.
- 2022Trial resultPROpelPROpel reported
rPFS HR 0.
- 2022MilestonePROpelPROpel and MAGNITUDE: PARP inhibitor plus abiraterone
A milestone in how this cancer is treated.
2021 · 3
May 2020 · 1
2020 · 3
2018 · 1
2013 · 3
2012 · 3
2011 · 2
2010 · 3
- 2010ApprovalCabazitaxelCabazitaxel approved in US
mCRPC after docetaxel
- 2010ApprovalSipuleucel-TSipuleucel-T approved in US
Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
- 2010MilestoneCabazitaxelCabazitaxel and sipuleucel-T approved
A milestone in how this cancer is treated.